Citadel Advisors
VYGR icon

Citadel Advisors’s Voyager Therapeutics VYGR Stock Holding History

Citadel Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,500
Closed -$52.1K – 14974
2026
Q1 		$52.1K Buy
+13,500
New +$53.1K ﹤0.01% 12393
2025
Q2 		– Sell
-37,700
Closed -$127K – 15321
2025
Q1 		$127K Buy
37,700
+14,700
+64% +$68.7K ﹤0.01% 11121
2024
Q4 		$130K Buy
23,000
+14,200
+161% +$91.5K ﹤0.01% 11087
2024
Q3 		$51.5K Sell
8,800
-7,000
-44% -$50.9K ﹤0.01% 11876
2024
Q2 		$125K Sell
15,800
-10,300
-39% -$86.3K ﹤0.01% 10600
2024
Q1 		$243K Buy
26,100
+21,100
+422% +$178K ﹤0.01% 9917
2023
Q4 		$42.2K Sell
5,000
-8,300
-62% -$60.2K ﹤0.01% 11964
2023
Q3 		$103K Buy
13,300
+3,500
+36% +$32K ﹤0.01% 10856
2023
Q2 		$112K Sell
9,800
-2,900
-23% -$30K ﹤0.01% 10752
2023
Q1 		$97.9K Buy
12,700
+11,500
+958% +$91.5K ﹤0.01% 11299
2022
Q4 		$7.32K Buy
+1,200
New +$6.82K ﹤0.01% 13832
2022
Q2 		– Sell
-13,800
Closed -$105K – 14218
2022
Q1 		$105K Sell
13,800
-11,200
-45% -$50K ﹤0.01% 12242
2021
Q4 		$68K Buy
25,000
+2,300
+10% +$7.85K ﹤0.01% 13054
2021
Q3 		$60K Sell
22,700
-110,800
-83% -$360K ﹤0.01% 13267
2021
Q2 		$551K Sell
133,500
-52,200
-28% -$237K ﹤0.01% 9857
2021
Q1 		$875K Buy
185,700
+27,800
+18% +$190K ﹤0.01% 8428
2020
Q4 		$1.13M Buy
+157,900
New +$1.52M ﹤0.01% 6547
2019
Q3 		– Sell
-11,000
Closed -$299K – 9812
2019
Q2 		$299K Buy
+11,000
New +$252K ﹤0.01% 7592

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors's VYGR Position: Q2 2026 in Review

Citadel Advisors increased its Voyager Therapeutics (VYGR) stake by 115% in Q2 2026, buying an estimated $1.59M and bringing the position to 784,067 shares worth $2.74M. The position accounts for ﹤0.01% of the portfolio, ranked #5848.

Citadel Advisors first reported a position in VYGR in Q3 2017 and has held it in 33 quarters since. The position peaked at $8.95M in Q3 2020. 135 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Citadel Advisors held 784,067 shares of Voyager Therapeutics worth $2.74M as of Q2 2026.
  • Citadel Advisors bought 419,403 Voyager Therapeutics shares in Q2 2026, an estimated $1.59M.
  • Voyager Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5848 holding.
  • Citadel Advisors first reported a position in Voyager Therapeutics in Q3 2017 and has held it in 33 quarters since.
  • Citadel Advisors's Voyager Therapeutics position peaked at $8.95M in Q3 2020.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.